CORRECTED-UK's Aptamer H1 revenue rises on new pharma contracts

Corrects Key Details table to say company reported loss per share and loss per basic share

Overview

• UK synthetic binder developer's H1 revenue grew 27% yr/yr, reflecting increased commercial traction

• Adjusted EBITDA loss narrowed to £1.0 mln as revenue improved and costs remained lean

• Company launched Accelerated Book Build to raise at least £3.75 mln, extending cash runway to 2028

Outlook

• Aptamer expects cash runway to extend through to 2028 after recent fundraising

• Company aims to convert asset portfolio into recurring royalty and licensing revenues

• Aptamer targets in vivo data for radiopharmaceutical pipeline by end of 2026

• Increased manufacturing capacity and quality audits to support supply of licensed assets and improve margins

Result Drivers

• PHARMA CONTRACTS - Revenue growth driven by new and repeat fee-for-service contracts with top pharmaceutical companies, including a major contract win in radioligand therapy

• LICENSING REVENUE - Initial licensing payments received from out-licensed Optimer assets to Twist Bioscience and Alphazyme, with additional licensing discussions underway

Company press release: ID:nRSY0113Ya

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)